Traws Pharma, Inc. (TRAW)
(Delayed Data from NSDQ)
$1.50 USD
-0.03 (-1.65%)
Updated Aug 7, 2025 12:02 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRAW 1.50 -0.03(-1.65%)
Will TRAW be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRAW based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for TRAW
Traws Pharma (TRAW) Seeks Regulatory Pathways for Antiviral Treatments
Traws Pharma advances antiviral pipeline with multiple regulatory submissions
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions | TRAW Stock News
Traws Pharma announced multiple regulatory submissions
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket